EAU 2024热点速递:肌层浸润性膀胱癌的临床进展  

Highlights from EAU 2024:the clinical advances in muscle-invasive bladder cancer

作　　者：王淼 章小平 WANG Miao;ZHANG Xiaoping(Department of Urology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院泌尿外科,武汉430022

出　　处：《临床泌尿外科杂志》2024年第6期547-550,共4页Journal of Clinical Urology

摘　　要：2024年欧洲泌尿外科协会(EAU)年会于4月5日—8日在法国巴黎召开,展示了全球泌尿外科领域的最新进展。肌层浸润性膀胱癌(muscle-invasive bladder cancer,MIBC)的临床进展主要集中在新辅助免疫治疗与新辅助化疗联合免疫治疗、根治性膀胱切除术中淋巴结清扫术的范围、转移性膀胱癌的治疗进展等3个方面,本文就相关内容作简要介绍。The Annual European Association of Urology(EAU)Congress was held in Paris,France,from April 5th to 8th,2024,showing the latest developments in the field of urology worldwide.The clinical advances in muscle-invasive bladder cancer(MIBC)mainly focus on three aspects:role of neoadjuvant immunotherapy and chemo-immunotherapy,extent of lymphadectomy in radical cystectomy,and the treatment progress in metastatic bladder cancer.This article provides a brief introduction to the relevant contents.

关 键 词：肌层浸润性膀胱癌 新辅助治疗 免疫治疗 联合治疗 

分 类 号：R737.14[医药卫生—肿瘤]